Crispr (CRSP) Stock
Key stats
- Market cap
- $4.44B
- Price / Earnings ratio
- -9.6x
- EPS (TTM)
- -$4.72
- Volume
- Loading
- 52-week high
- $63.45
- 52-week low
- $44.12
- EPS vs analyst estimate
- +10.0%Q3 FY25 · -$1.17 vs -$1.30
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with CRSP
Recent news

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRSP

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
CRSP

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CRSP

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRSP
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 37.64
- MACD 12/26/9
- -1.41
- EMA 9 of MACD
- -0.98
- MACD histogram
- -0.42
- SMA 50
- $52.66
- Price below SMA 50
- EMA 50
- $51.78
- Price below EMA 50
- SMA 200
- $52.64
- Price below SMA 200
- EMA 200
- $52.86
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.14 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRSP

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
CRSP

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CRSP

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRSP

3 Promising Genomics Stocks to Add to Your Portfolio Now
3 Promising Genomics Stocks to Add to Your Portfolio Now
CRSP

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
CRSP

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
CRSP

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRSP

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRSP

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
CRSP
News tone: automated (AI) classification of the article's content, not a price prediction.
About Crispr
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Samarth Kulkarni Ph.D. | CEO & Chairman | 1978 |
| Dr. Naimish Patel C.M., M.D. | Chief Medical Officer | 1972 |
| Mr. Shaun Foy CFA | Co-Founder | — |
| Dr. Emmanuelle Marie Charpentier Ph.D. | Co-Founder & Scientific Advisory Board Member | — |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member | — |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder | 1972 |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member | 1965 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.64
- MACD 12/26/9
- -1.41
- EMA 9 of MACD
- -0.98
- MACD histogram
- -0.42
- SMA 50
- $52.66
- Price below SMA 50
- EMA 50
- $51.78
- Price below EMA 50
- SMA 200
- $52.64
- Price below SMA 200
- EMA 200
- $52.86
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $52.00
- Average
- $74.80
- High
- $90.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.1 | +0.7 | ||||||||||
| 2022 | -19.5 | -6.3 | +9.3 | -25.0 | +11.7 | +5.0 | +17.6 | -12.1 | -0.4 | -17.1 | +5.3 | -25.2 |
| 2023 | +24.4 | -5.8 | -5.2 | +8.1 | +30.5 | -13.0 | +1.9 | -11.3 | -10.2 | -8.2 | +52.5 | -8.8 |
| 2024 | -4.7 | +30.2 | -18.6 | -22.3 | -0.1 | -5.5 | +6.2 | -13.0 | +3.2 | +1.8 | +0.8 | -28.6 |
| 2025 | +0.4 | +9.8 | -19.5 | +16.7 | -3.8 | +31.6 | +16.0 | -7.6 | +23.1 | -3.3 | -13.7 | +0.5 |
| 2026 | -7.1 | +17.2 | -21.7 | +7.2 | +8.8 | +0.6 | -13.7 | +14.9 | -2.6 | -7.3 | -8.5 |



